title: Effects of dopamine, NMDA, opiate, and serotonin-related agents on acute methamphetamine-induced self-injurious behavior in mice.
abstract: We examined the biochemical processes responsible for acute methamphetamine (MAP)-induced self-injurious behavior (SIB) in mice. In initial experiments, a single dose of MAP (5, 10, or 15 mg/kg, IP) or an equivalent volume of saline was administered to male BALB/c mice. Acute MAP administration dose dependently increased the incidence of SIB (p < 0.05). In further experiments, we evaluated the effects of SCH23390, sulpiride, MK-801, naloxone or 5-hydroxy-L-tryptophan (5-HTP) on the incidence of acute MAP (15 mg/kg, IP)-induced SIB. Both SCH23390 (0.5 and 1.0 mg/kg, IP) and 5-HTP (100 and 200 mg/kg, IP) reduced the incidence of MAP-induced SIB (p < 0.05). MK-801 (0.125 and 0.25 mg/kg, IP) completely blocked the SIB induced by MAP (p < 0.001). In contrast, neither sulpiride (25, 50, and 100 mg/kg, IP) nor naloxone (1, 5, and 10 mg/kg, IP) affected the incidence of MAP-induced SIB. It is concluded that dopamine D(1), NMDA, and serotonin neurotransmission may be involved in critical biochemical processes responsible for acute MAP-induced SIB.
authors.affiliation: Department of Neuropsychiatry, School of Medicine, Fukushima Medical University, 1-Hikarigaoka, 960-1295, Fukushima City, Fukushima, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Shishido
authors.forename: Y
authors.initials: Y
authors.lastname: Watanabe
authors.forename: K
authors.initials: K
authors.lastname: Kato
authors.forename: R
authors.initials: R
authors.lastname: Horikoshi
authors.forename: S I
authors.initials: SI
authors.lastname: Niwa
mesh_terms: D006916:5-Hydroxytryptophan / Q000494:pharmacology; D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D016291:Dizocilpine Maleate / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D008297:Male; D008694:Methamphetamine / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009043:Motor Activity / Q000187:drug effects; D016202:N-Methylaspartate / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009294:Narcotics / Q000494:pharmacology; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D016728:Self-Injurious Behavior / Q000139:chemically induced* / Q000188:drug therapy / Q000523:psychology; D018490:Serotonin Agents / Q000494:pharmacology; D013469:Sulpiride / Q000494:pharmacology
chemical_list: D001552:Benzazepines; D018492:Dopamine Antagonists; D018691:Excitatory Amino Acid Antagonists; D009292:Narcotic Antagonists; D009294:Narcotics; D016194:Receptors, N-Methyl-D-Aspartate; D018490:Serotonin Agents; D009270:Naloxone; D008694:Methamphetamine; D016202:N-Methylaspartate; D016291:Dizocilpine Maleate; D013469:Sulpiride; D006916:5-Hydroxytryptophan; D004298:Dopamine